Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLA-015
- Development stage
- Unknown
- Lead developer
- Glatt Pharmaceutical Services
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GLA-015 is a novel cannabidiol (CBD) granules formulation developed by Glatt Pharmaceutical Services GmbH & Co. KG. It is intended for the treatment of Coronavirus disease 2019 (COVID-19). This new formulation is designed to offer enhanced solubility, increased bioavailability, reduced variability, especially in the fasted state, and improved robustness towards food interaction compared to existing oil-based cannabidiol solutions.
- Brand names
- Nantheia A1002
- Other names
- Cannabidiol 1500 mg 29,7% w/w GRA BLD P
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)Cyp (Cyclophilin family)FAAHGABRR (GABA-A receptor subunit rho)GPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)UGT (UDP-glucuronosyltransferase family)ADORA2A (Adenosine A₂A Receptor)Glycine receptorKCNQ (Potassium voltage-gated channel subfamily Q (Kv7))MOR (Mu opioid receptor)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV2 (Transient receptor potential cation channel subfamily V member 2)TRPV3 (Transient receptor potential vanilloid subtype 3)TRPV4 (Transient receptor potential cation channel subfamily V member 4)
Beyond the preview
Go deeper on GLA-015.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLA-015.